Related Experiment Video
Updated: Jun 13, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Generic penetration in the retail atypical antipsychotic market
Susan Lenderts1, Amir H Kalali, Peter Buckley
1Ms. Lenderts is Manager, Strategic Analytics, Quintiles Commercial, Falls Church, Virginia.
Abstract:
In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
